Novel naphthylsulfonic acids and related compounds as glucose uptake agonists

Methods for treating conditions associated with hyperglycemia, especially Type II diabetes, with novel naphthyl-sulfonic acids and related compounds are provided. Compounds of formula (1) where: R1 and R2 are, independently, hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, R3 is a substituent on the B ring; and is -SO2OR6, -C(O)OR6, -SO2NR62-C(O)NR62 or tetrazolyl; the linker -WY- between the naphthyl and phenyl intersects the A ring of the naphthyl and is, independently, -C(O)NR7-, -NR7C(O)-, -C(O)O-, -OC(O)-, -CH=CH-, -NR7CH2-, -CH2NR7-, -NR7C(O)NR7- -NR7C(O)O-, -OC(O)NR7-, -NR7SO2O-, -OSO2NR7-, -OC(O)O-, -SO2NR7-, -NR7SO2-, -OSO2-, or -SO20-; each R6 and R7 is, independently, hydrogen or lower alkyl; optionally in the form of single stereoisomers or mixtures of stereoisomers, or the pharmaceutically acceptable salts thereof; are useful in methods of stimulating the kinase activity of the insulin receptor, enhancing the activation of the insulin receptor by insulin, and stimulating the uptake of glucose into cells. A variety of antidiabetic compounds and pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.

Novel naphthylsulfonic acids and related compounds as glucose uptake agonists

Novel naphthylsulfonic acids and related compounds as glucose uptake agonists

Methods for treating conditions associated with hyperglycemia, especially Type II diabetes, with novel naphthyl-sulfonic acids and related compounds are provided. Compounds of formula (1) where: R1 and R2 are, independently, hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, R3 is a substituent on the B ring; and is -SO2OR6, -C(O)OR6, -SO2NR62-C(O)NR62 or tetrazolyl; the linker -WY- between the naphthyl and phenyl intersects the A ring of the naphthyl and is, independently, -C(O)NR7-, -NR7C(O)-, -C(O)O-, -OC(O)-, -CH=CH-, -NR7CH2-, -CH2NR7-, -NR7C(O)NR7- -NR7C(O)O-, -OC(O)NR7-, -NR7SO2O-, -OSO2NR7-, -OC(O)O-, -SO2NR7-, -NR7SO2-, -OSO2-, or -SO20-; each R6 and R7 is, independently, hydrogen or lower alkyl; optionally in the form of single stereoisomers or mixtures of stereoisomers, or the pharmaceutically acceptable salts thereof; are useful in methods of stimulating the kinase activity of the insulin receptor, enhancing the activation of the insulin receptor by insulin, and stimulating the uptake of glucose into cells. A variety of antidiabetic compounds and pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.

Dimers from hexafluoropropene and propylene

System and method of generating associations

A method for automatically generating associations of items included in a database. A user first specifies a support criteria indicating a strength of desired associations of items contained in the said database. Then, a recursive program is executed for generating a hierarchical tree structure comprising one or more levels of database itemsets, with each itemset representing item associations determined to have satisfied the specified support criteria. The recursive program includes steps of: characterizing nodes of the tree structure as being either active and enabling generation of new nodes at a new level of the tree, or inactive, at any given time; enabling traversal of the tree structure in a predetermined manner and projecting each of the transactions included in the database onto currently active nodes of the tree structure to generate projected transaction results; and, counting the projected transaction results of the projected transactions at the active nodes to determine whether the further itemsets satisfy the specified support criteria. All itemsets meeting the specified support criteria are added to the tree structure at a new level.

Air distributing device

Nanofibrous material especially for topical use in therapies

Nanovlákenný materiál zejména pro topické použití při terapiích tvořený látkou ze skupiny lipofosfonoxinů obecného vzorce I, kde R1 je (C8–C22)alkyl, hexadecyloxypropyl, tetradecyloxypropyl, tetradecyloxyetyl nebo hexadecyloxyetyl, R2 je uracil, thymin nebo cytosin, a R3 je primární, sekundární nebo terciární amin, diastereomery a směsi diastereomerů sloučenin obecného vzorce I a jejich farmaceuticky přijatelné soli a hydráty, inkorporovanou do nanovláken na bázi polyesteru obecného vzorce II, kde m nabývá hodnoty alespoň 1, a R je -H nebo (C1–C10)alkyl, nebo jeho kopolymerů. Nanofibrous material especially for topical use in therapies consisting of a lipophosphonoxin group of formula I, wherein R 1 is (C 8 -C 22) alkyl, hexadecyloxypropyl, tetradecyloxypropyl, tetradecyloxyethyl or hexadecyloxyethyl, R 2 is uracil, thymine or cytosine, and R 3 is primary, secondary or tertiary amine, diastereomers and mixtures of diastereomers of compounds of formula I and their pharmaceutically acceptable salts and hydrates, incorporated into polyester-based nanofibers of formula II, wherein m is at least 1, and R is -H or (C1-C10) alkyl, or its copolymers.

Nuovi acidi naftilsolfonici e composti ad essi correlati utli come agonisti dell'assorbimento del glucosio.

Sheet mill roll cooling

Procedimiento para la detección de apertura de puertas en ascensores y circuito para la puesta en práctica del mismo

La presente invención de refiere a un método para la detección del número de puertas abiertas de un ascensor. El método es de aplicación en la seguridad del ascensor, en concreto en la prevención de accesos no autorizados al hueco del ascensor. De forma más concreta, el método propuesto está basado en la inyección de una señal periódica en la línea de seguridad del ascensor, por la que circula una corriente que se verá interrumpida al abrir una puerta. Adicionalmente, mediante una circuitería adecuada, se inducirá un desfase a la señal cada vez que se abra una puerta, utilizándose dicho desfase para monitorizar el número de puertas abiertas en un instante determinado. Es asimismo objeto de la invención el circuito con el que llevar a cabo el procedimiento de detección de apertura de puertas.

Verfahren zurStromversorgung von in der Lichtleistung geregelten Leuchtstofflampen

Sheet mill roll cooling

Procedimiento para la detección de apertura de puertas en ascensores y circuito para la puesta en práctica del mismo

La presente invención de refiere a un método para la detección del número de puertas abiertas de un ascensor. El método es de aplicación en la seguridad del ascensor, en concreto en la prevención de accesos no autorizados al hueco del ascensor. De forma más concreta, el método propuesto está basado en la inyección de una señal periódica en la línea de seguridad del ascensor, por la que circula una corriente que se verá interrumpida al abrir una puerta. Adicionalmente, mediante una circuitería adecuada, se inducirá un desfase a la señal cada vez que se abra una puerta, utilizándose dicho desfase para monitorizar el número de puertas abiertas en un instante determinado. Es asimismo objeto de la invención el circuito con el que llevar a cabo el procedimiento de detección de apertura de puertas.

Meßeinrichtung für eine automatische Werkzeugmaschine, insbesondere Schleifmaschine

Verfahren und Vorrichtung zum Herstellen eines kalibrierten Kartonrohres mit glatter Oberflaeche

Benzoltricarbonsäureamide als aktivatoren des insulinrezeptors

Elektroakustischer Wandler

Verfahren zum Bedrucken von Gegenständen aus synthetischen thermoplastischen Harzen

Air distributing device

Making self-twisted fibrous product from atleast two strands

对血清素受体具有亲和力、可用作治疗剂的新型四环芳基磺酰吲哚、其制备方法及其药物组合物

本发明涉及新型四环芳基磺酰吲哚、其衍生物、类似物、互变异构体、立体异构体、多晶型物、药学上可以接受的盐、药学上可以接受的溶剂化物、此处所述的新型中间体及其药学上可以接受的组合物。本发明特别涉及通式(I)所述的新型四环芳基磺酰吲哚、其衍生物、类似物、互变异构体、立体异构体、多晶型物、药学上可以接受的盐、药学上可以接受的溶剂化物、此处所述的新型中间体及其药学上可以接受的组合物。本发明还涉及制备通式(I)所述化合物、包含有效量该化合物的组合物的方法以及该化合物/组合物在治疗中的应用。

Polypropylene blends of improved dyeability

Zwischenantrieb für Förderbänder mit Rundgliederketten

Making self-twisted fibrous product from atleast two strands

Method for identification of insulin receptor kinase activators

Method for identification of insulin receptor kinase activators

A method to determine whether a compound is an insulin receptor kinase activator by: concurrently administering the compound, an effective amount of an HIV protease inhibitor, and an effective amount of glucose to a non-human mammal and measuring the concentration of insulin or glucose in the blood of the non human mammal, where a concentration of insulin or glucose in the blood of the non-human mammal that is lower than the concentration in the blood of a comparable non-human mammal that has been concurrently administered the HIV protease inhibitor and glucose but non administered the compound, shows that the compound is an insulin receptor kinase activator.

Method for identification of insulin receptor kinase activators

Substituierte Diäthinylcarbinole

盐酸埃克替尼的固体形式及其制备工艺

本申请的诸方面涉及盐酸埃克替尼的固体形式及其药物组合物。具体方面涉及盐酸埃克替尼的结晶形式。其他方面涉及制备盐酸埃克替尼的结晶形式的工艺。

盐酸埃克替尼的固体形式及其制备工艺

本申请的诸方面涉及盐酸埃克替尼的固体形式及其药物组合物。具体方面涉及盐酸埃克替尼的结晶形式。其他方面涉及制备盐酸埃克替尼的结晶形式的工艺。

艾日布林及其中间体的制备方法

本申请涉及制备式II的四氢呋喃化合物、式V的4‑亚甲基四氢呋喃化合物和式IX的四氢吡喃化合物的方法，这些化合物可用作制备诸如艾日布林或其药学上可接受的盐的软海绵素B类似物的中间体。